vol1 - Page 311
Page 311
Previous ,
Next ,
Original Image
Return to Index
that directly relate to medical use and safety under medical
supervision, w7_/ o
In its brief, DEA goes one step further -_ expanding
upon the #safety and efficacy # requirements of the NDA procedure_
by requiring inflated efficacy and safety demonstrations.
---iDEA expands the efficacy requirement, rejected by the
FirstCircuit, in two ways° First, the Agency appears to requi__
that marijuana not only be effective, but that it also be the
...... most effective drug for each indication discussed in this case°
Second, the Agency appears to state that the only means of
showing efficacy is through the use of double-blindt randomized
studies. This interpretation is unquestionably invalid and wou3
not withstand even the most cursory judicial review.
Virtually ignoring the overwhelming evidence of
marijuanaSs medical utility offered by the Alliance, NORML and
the other proponents for rescheduling in this proceeding, the
Agency focuses first on whether marijuana is deflective, n and
then apparently requires marijuana to be the perfect drug --
i.e., the _most effective # drug available for every patient in
every treatment situation. _/ Not only does this requirement
aggravate one of the aspects of the standard that the First
Circuit found most loathsome, but it cannot withstand logical
analysis o
Z/ DEA Brief at 95. A review of the standard, cited by DEA in
its brief, confirms that this is the case. /__ at 85-86.
_/ °DFEA Brief at _ 42-45, pp. 28_2go
Previous ,
Next ,
Return to Index